Navocaftor by Sionna Therapeutics for Cystic Fibrosis: Likelihood of Approval

A dose-reduction strategy for a commonly used first-line combination in pancreatic cancer resulted in similar survival outcomes but improved tolerability, a randomized phase II study

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to un­der­writ­ers pitch­ing in. Io­vance